We are live on ! Find out more
MXCT icon

MaxCyte

108 hedge funds and large institutions have $452M invested in MaxCyte in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

41% more capital invested

Capital invested by funds: $321M → $452M (+$131M)

34% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 29

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

6% more funds holding

Funds holding: 102108 (+6)

1.44% more ownership

Funds ownership: 66.98%68.42% (+1.4%)

Holders
108
Holders Change
+6
Holders Change %
+5.88%
% of All Funds
1.86%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
18
Increased
39
Reduced
29
Closed
11
Calls
$99K
Puts
Net Calls
+$99K
Net Calls Change
+$14K

MXCT Hedge Fund Activity: Q3 2022 in Review

108 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in MaxCyte (MXCT) for Q3 2022, worth a combined $452M — up 41% from $321M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new MXCT positions and 11 closed out — a net gain of 7 holders — while 39 added to existing stakes and 29 trimmed.

The largest buyer was Blue Water Life Science Advisors, opening a new position worth an estimated $18M. The largest seller was Casdin Capital, cutting an estimated $18M.

  • 108 institutional investors held MaxCyte (MXCT) as of Q3 2022, up from 102 in Q2 2022.
  • Funds reported $452M of MaxCyte stock for Q3 2022, up 41% quarter-over-quarter.
  • 18 funds opened new MaxCyte positions in Q3 2022 and 11 closed out, a net change of +7 holders.
  • The largest MaxCyte buyer in Q3 2022 was Blue Water Life Science Advisors, an estimated $18M added.
  • The largest MaxCyte seller in Q3 2022 was Casdin Capital, an estimated $18M sold.

Based on aggregated 13F filings for Q3 2022.